- Sangamo BioSciences' (SGMO) first clinical study, a phase 1 trial conducted on six HIV-positive patients over 12 weeks, demonstrates that the T-cell genome can be safely engineered to mimic a naturally occurring mutation that provides resistance to HIV infection. This could potentially be a way to control HIV infection without the use of drugs.
- In the study, T-cells from the subjects were isolated and edited with ZFNs to make them resistant to the HIV virus by knocking out the CCR5 gene that encodes a coreceptor required for infection. The altered cells, SB-728-T, were returned to the subjects via autologous infusion.
- The ZFN-modified cells showed preferential survival over unmodified cells and were able to persist and circulate throughout the body to key reservoirs of HIV infection such as gut-associated lymphoid tissue.
- Shares are up 14% in early trading.
From other sites
at Zacks.com (Mar 3, 2015)
at Benzinga.com (Jan 12, 2015)
at CNBC.com (Jan 9, 2015)
at Benzinga.com (Dec 17, 2014)
at CNBC.com (Sep 9, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs